A frequent nonsense mutation in exon 1 across certain HLA-A and HLA-B alleles in leukocytes of patients with acquired aplastic anemia

Leukocytes that lack expression of HLA alleles are frequently detected in patients with acquired aplastic anemia (AA) who respond to immunosuppressive therapy, although the exact mechanisms underlying the HLA loss and HLA allele repertoire likely to acquire loss-of-function mutations are unknown. We identified a common nonsense mutation at codon 19 (c.19C>T, p.R7X) in exon 1 (Exon1(mut)) of different HLA-A and -B alleles in HLA-lacking granulocytes from AA patients. A droplet digital polymerase chain reaction assay capable of detecting as few as 0.07% Exon1(mut) HLA alleles in total DNA revealed that the mutation was present in 29% (101/353) of AA patients, with a median allele frequency of 0.42% (range, 0.071% to 21.3%). Exon1(mut) occurred in only 12 different HLA-A (n=4) and HLA-B (n=8) alleles, including B*40:02 (n=31) and A*02:06 (n=15), which correspond to four HLA class I supertypes (A02, A03, B07, and B44). The percentages of patients who possessed at least one of these 12 HLA alleles were significantly higher in the 353 AA patients (92%, P<0.001) and in 83 AA patients with copy number neutral loss of heterozygosity in chromosome 6p (100%, P<0.001) than the percentage (81%) in 18,604 Japanese healthy individuals. Eighty-two percent (37/45) of AA patients with Exon1(mut) responded to immunosuppressive therapy. Small populations of leukocytes that lack particular HLA-A or B alleles due to Exon1(mut) are common in AA patients. The detection of Exon1(mut) using a droplet digital polymerase chain reaction assay without the need for HLA typing may serve as a powerful tool for diagnosing the immune pathophysiology of patients with bone marrow failure.